Mangoceuticals (MGRX) Cost of Revenue (2023 - 2026)

Mangoceuticals has disclosed Cost of Revenue across 4 years of filings, most recently posting $8218.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $8218.0, down 66.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $37903.0 (down 61.02% YoY), and the FY2025 annual result was $54422.0, down 41.67% from the prior year.
• Cost of Revenue came in at $8218.0 for Q1 2026 at Mangoceuticals, down from $8511.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $53362.0 in Q4 2023 to a low of $2359.0 in Q3 2025.
• The 4-year median for Cost of Revenue is $21505.0 (2024), against an average of $23910.5.
• Peak annual rise in Cost of Revenue reached 18.96% in 2025, while the deepest fall reached 89.03% in 2025.
• Mangoceuticals' Cost of Revenue stood at $53362.0 in 2023, then sank by 60.03% to $21331.0 in 2024, then slumped by 60.1% to $8511.0 in 2025, then declined by 3.44% to $8218.0 in 2026.
• The last three Cost of Revenue figures came in at $8218.0 (Q1 2026), $8511.0 (Q4 2025), and $2359.0 (Q3 2025), per Business Quant data.